EXEL
Price:
$25.15
Market Cap:
$7.17B
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and...[Read more]
Industry
Biotechnology
IPO Date
2000-04-17
Stock Exchange
NASDAQ
Ticker
EXEL
According to Exelixis, Inc.’s latest financial reports and current stock price. The company's current ROE is 15.80%. This represents a change of 289.16% compared to the average of 4.06% of the last 4 quarters.
The mean historical ROE of Exelixis, Inc. over the last ten years is 47.76%. The current 15.80% ROE has changed -66.92% with respect to the historical average. Over the past ten years (40 quarters), EXEL's ROE was at its highest in in the September 2014 quarter at 106.92%. The ROE was at its lowest in in the September 2016 quarter at -35.24%.
Average
47.76%
Median
14.75%
Minimum
-78.62%
Maximum
233.86%
Discovering the peaks and valleys of Exelixis, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 75.71%
Maximum Annual ROE = 233.86%
Minimum Annual Increase = -168.84%
Minimum Annual ROE = -78.62%
Year | ROE | Change |
---|---|---|
2023 | 9.18% | 25.28% |
2022 | 7.33% | -29.92% |
2021 | 10.45% | 75.71% |
2021 | 5.95% | -68.76% |
2020 | 19.04% | -64.48% |
2018 | 53.60% | -0.97% |
2017 | 54.12% | -168.84% |
2016 | -78.62% | -148.31% |
2016 | 162.73% | -30.42% |
2014 | 233.86% | -163.29% |
The current ROE of Exelixis, Inc. (EXEL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
8.98%
5-year avg
10.39%
10-year avg
47.76%
Exelixis, Inc.’s ROE is greater than TG Therapeutics, Inc. (-38.21%), greater than Viking Therapeutics, Inc. (-15.05%), greater than Madrigal Pharmaceuticals, Inc. (-95.61%), less than BioXcel Therapeutics, Inc. (176.93%), less than BioMarin Pharmaceutical Inc. (5.08%), greater than Seagen Inc. (-28.06%), less than Alnylam Pharmaceuticals, Inc. (47.92%), less than Halozyme Therapeutics, Inc. (168.60%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than PDS Biotechnology Corporation (-137.06%), less than PTC Therapeutics, Inc. (57.03%), less than Reata Pharmaceuticals, Inc. (19.32%), greater than Intercept Pharmaceuticals, Inc. (-78.24%), less than Krystal Biotech, Inc. (13.36%), greater than Kodiak Sciences Inc. (-77.23%), less than Sarepta Therapeutics, Inc. (5.17%), greater than Mirati Therapeutics, Inc. (-81.10%),
Company | ROE | Market cap |
---|---|---|
-38.21% | $3.41B | |
-15.05% | $6.00B | |
-95.61% | $5.30B | |
176.93% | $22.26M | |
5.08% | $16.01B | |
-28.06% | $43.15B | |
47.92% | $31.68B | |
168.60% | $7.50B | |
32.93% | $109.78M | |
-137.06% | $107.88M | |
57.03% | $2.43B | |
19.32% | $6.57B | |
-78.24% | $794.69M | |
13.36% | $5.29B | |
-77.23% | $121.54M | |
5.17% | $12.29B | |
-81.10% | $4.12B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Exelixis, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Exelixis, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Exelixis, Inc.'s ROE?
How is the ROE calculated for Exelixis, Inc. (EXEL)?
What is the highest ROE for Exelixis, Inc. (EXEL)?
What is the 3-year average ROE for Exelixis, Inc. (EXEL)?
What is the 5-year average ROE for Exelixis, Inc. (EXEL)?
How does the current ROE for Exelixis, Inc. (EXEL) compare to its historical average?